Pharma: Clinic Roundup
Monday, July 8, 2013
The FDA has approved new labeling for Isentress (raltegravir), by Merck & Co. Inc., of Whitehouse Station, N.J. Including 240-week results from the STARTMRK study, a double-blind, Phase III noninferiority trial evaluating an integrase inhibitor for treatment-naive adults patients with HIV-1 infection.
Outside of the US
Part of Thomson Reuters
Note: our contact information has changed
In the U.S. and Canada: +1-800-336-4474
Outside the U.S.: +44-203-684-1796
Hours: Monday - Friday, 8:00am - 6:00 pm EST
© 2017 Thomson Reuters. Reproduction, reposting content is strictly prohibited.